Location History:
- Saar, DE (2000)
- Homburg/Saar, DE (1999 - 2008)
Company Filing History:
16 out of 525 
1 out of 560 
1 out of 2,885 
Years Active: 1999-2008
Title: The Innovative Work of Ugur Sahin: Pioneering Contributions in Cancer Research
Introduction
Ugur Sahin, a renowned inventor based in Homburg/Saar, Germany, has made significant contributions to the field of cancer research with a total of 17 patents to his name. His groundbreaking work focuses on developing peptides and nucleic acid molecules that bind to MHC Class II molecules and have shown promising results in tumor rejection antigen precursors such as NY-ESO-1 and SSX-2.
Latest Patents
Sahin's latest patents include "Isolated peptides which bind to MHC Class II molecules, and uses thereof," which details peptides with amino acid sequences found in tumor rejection antigen precursors like NY-ESO-1 and SSX-2. These peptides bind to MHC-Class II molecules, promoting the proliferation of CD4+ cells. Additionally, his patent on "Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof" explores peptides derived from SSX molecules and NY-ESO-1, forming complexes with HLA molecules that trigger cell lysis by cytolytic T cells.
Career Highlights
Sahin has been associated with the Ludwig Institute for Cancer Research Limited, a prominent organization known for its innovative cancer research initiatives. His work at the institute has led to groundbreaking discoveries in the development of novel cancer therapies based on the body's immune response mechanisms. Sahin's expertise in molecular biology and immunology has paved the way for novel treatment approaches in oncology.
Collaborations
Throughout his career, Sahin has collaborated with esteemed professionals in the field, including Michael Pfreundschuh and Ozlem Tureci. Together, they have worked on cutting-edge research projects aimed at revolutionizing cancer treatment strategies. These collaborations have resulted in the successful development and patenting of innovative technologies that have the potential to transform the landscape of cancer immunotherapy.
Conclusion
Ugur Sahin's dedication to advancing cancer research through innovative inventions and patents is truly commendable. His pioneering work in developing peptides and nucleic acid molecules for cancer immunotherapy highlights the importance of harnessing the power of the immune system in combating cancer. Sahin's contributions have the potential to make a significant impact on the field of oncology, offering new hope for patients worldwide.